Telomir Pharmaceuticals (NASDAQ: TELO) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for Telomir-Zn, the company's lead candidate, to treat advanced or metastatic triple-negative breast cancer. This clearance marks a significant milestone for the clinical-stage biotechnology company, allowing it to initiate a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing, and preliminary antitumor activity. The development is supported by preclinical pharmacology, toxicology, and biomarker data as the company advances toward clinical development.
The news is important because triple-negative breast cancer (TNBC) is a particularly aggressive form of breast cancer that lacks targeted treatment options, often leading to poor prognoses. According to the American Cancer Society, TNBC accounts for about 10-15% of all breast cancers but is more common in younger women and those with BRCA1 mutations. The approval of Telomir-Zn for clinical trials offers a potential new therapeutic avenue for patients who have limited treatment alternatives after standard therapies fail.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. These mechanisms are critical in cancer progression and resistance, making Telomir-Zn a promising candidate for further investigation.
The Phase 1/2 trial will assess the safety, tolerability, and preliminary efficacy of Telomir-Zn in patients with advanced or metastatic TNBC. If successful, the therapy could provide a new treatment option for a patient population with high unmet medical need. The FDA's clearance of the IND application underscores the potential of Telomir-Zn based on preclinical data, and investors and researchers will be closely watching the trial's outcomes.
For more information, the full press release is available at https://ibn.fm/p4e9J. The latest news and updates relating to TELO can be found in the company's newsroom at https://ibn.fm/TELO.
